Welcome to our dedicated page for Cryo-Cell Intl SEC filings (Ticker: CCEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cryo-Cell International, Inc. (CCEL) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-generated summaries to help interpret complex documents. As a NYSE American–listed company engaged in cellular processing, cryogenic storage, and cord blood banking, Cryo-Cell uses its SEC filings to report on financial performance, governance, financing arrangements, and material events.
Investors can review annual reports on Form 10-K for a comprehensive discussion of the company’s business, including its private and public cord blood banking operations, the role of PrepaCyte-CB processing technology, the ExtraVault biostorage offering, and the license agreement with Duke University. Quarterly reports on Form 10-Q provide interim financial data, segment revenue details such as processing and storage fees, public banking revenue, and product revenue, as well as updates on research and development spending and other operating items.
Current reports on Form 8-K document specific material events. Recent examples include disclosures about decisions to declare or not declare quarterly cash dividends, amendments to the company’s Credit Agreement with Susser Bank, and the setting of the annual meeting date and record date. These filings also describe changes to revolving credit commitments, maturity dates, and the addition of subsidiaries such as Celle Corp. as guarantors, which are relevant for understanding Cryo-Cell’s capital structure and liquidity.
The definitive proxy statement on Schedule DEF 14A outlines board composition, proposals for director elections, auditor ratification, and advisory votes on executive compensation, as well as stockholder voting procedures. Form 4 and related insider transaction reports, when available, can be used to track trading activity by directors and officers.
Stock Titan’s AI tools summarize key points from 10-K, 10-Q, 8-K, DEF 14A, and other filings, helping users quickly identify disclosures on dividends, credit facilities, governance matters, and strategic initiatives without reading every page of the original documents.
Cryo-Cell International (CCEL) announced it will not declare a quarterly cash dividend for the fourth quarter of fiscal 2025. The company stated that future dividends may or may not be paid, with decisions driven by financial performance, capital requirements, and strategic priorities.
This update signals a pause in cash distributions for Q4 FY2025 and places emphasis on deploying resources based on operating needs and strategic plans. The company’s stance leaves flexibility for future payouts if conditions align with its financial and strategic criteria.
Cryo-Cell International (CCEL) reported insider purchases by Chairman and Co-CEO David I. Portnoy. He acquired 4,666 shares of common stock on 10/31/2025 at $4.45 and 5,000 shares on 11/04/2025 at a weighted average price of $4.40.
Following these transactions, Portnoy beneficially owned 837,010 shares directly. He also reports additional indirect holdings through entities and family accounts, as listed in the filing.
Cryo-Cell International (CCEL) amended its credit facilities with Susser Bank. The Fifth Amendment adds wholly owned subsidiary Celle Corp. as a guarantor and updates key terms of the company’s revolving credit facility and term loan.
The revolving credit facility’s commitment was revised to $8,000,000 and its maturity extended to October 18, 2027. The term loan maturity was extended to July 29, 2032. The amendment also sets revised pricing: Base Rate margins of 4.25% for term loans and 3.75% for revolving loans, Monthly SOFR margins of 3.25% for term loans and 2.75% for revolving loans, and a 0.25% commitment fee.
Existing rate constructs and floors remain in place from the 2022 agreement, with the company able to elect Base Rate or Monthly SOFR-based interest. The changes extend maturities while reducing revolver capacity, and add collateral support via a Security Agreement benefiting the lenders.
Cryo-Cell International (CCEL) filed a Form 4 reporting a director equity award. On 10/21/2025, director Daniel Mizrahi received a grant of stock options to purchase 5,300 shares at $4.35 per share, expiring on 10/21/2035. The options vest at a rate of 1/12 per month commencing on 10/21/2025.
Following the reported transactions, the reporting person directly beneficially owned 30,634 shares of common stock. The filing also lists prior option grants of 5,300 shares each dated 10/20/2021, 10/03/2022, 10/10/2023, and 10/29/2024 with exercise prices of $12.63, $6.50, $4.90, and $5.82, respectively.
Cryo-Cell International (CCEL) director reported a new stock option grant. On 10/21/2025, the director received options for 5,300 shares at an exercise price of $4.35, exercisable on 10/21/2025 and expiring on 10/21/2035. Following the reported transactions, the director directly beneficially owned 57,901 shares of common stock. The filing also lists multiple prior stock option awards with various exercise prices and maturities.
Cryo-Cell International (CCEL) filed its quarterly report, showing stable operations with softer topline. Revenue for the quarter ended August 31, 2025 was $7.83 million versus $8.07 million a year ago, as public banking and product sales remained small. Operating income improved to $1.90 million from $1.39 million on lower cost of sales and SG&A. Net income was $0.75 million ($0.09 diluted EPS) compared with $1.05 million ($0.13) last year.
For the nine months, revenue was $23.72 million versus $23.96 million; net income was $1.39 million ($0.17 diluted EPS) versus $2.26 million ($0.27). Interest expense weighed on results at $0.54 million in the quarter and $1.58 million year-to-date.
Deferred revenue tied to long-term storage contracts rose to $59.58 million ($9.74 million current), supporting future revenue recognition. Cash was $265,207 with $2.96 million in marketable securities. The company reported a stockholders’ deficit of $14.83 million driven by deferred revenue accounting and treasury stock. Debt included a $3.20 million line of credit and $8.39 million term note. As of October 15, 2025, 8,055,150 common shares were outstanding.
The proxy discloses governance and shareholder procedural details for Cryo-Cell International, Inc. It states the Audit Committee charter defines the committees duties, membership rules and relationship with independent auditors and management but does not set director nomination procedures. The document lists exact stockholder nomination and proposal submission requirements, including identity, holdings, arrangements, nominee consents and intent to solicit or appear at the meeting. Beneficial ownership disclosures include Adam Fleishman reporting 279,000 shares held by his trust and 230,000 shares personally, and a Patent and Technology License with Duke University that issued 409,734 shares upon execution. Detailed ownership allocations are provided for David Portnoy and Mark Portnoy (including 401(k), IRA, individual holdings, related-entity holdings and numerous option pools). Multiple stock option vesting schedules and executive post-termination benefits for disability and death (including two times base salary and continued insurance coverage) plus non-compete and non-solicit restrictions are described.
David Portnoy, Chairman and Co-CEO of Cryo-Cell International, Inc. (CCEL), reported multiple open-market purchases of the company's common stock on September 16-18, 2025. He acquired 6,449 shares on 09/16/2025 at a weighted average price of $4.46, 5,564 shares on 09/17/2025 at $4.43, and 3,411 plus 1,751 shares on 09/18/2025 at weighted averages around $4.46 and $4.49 respectively. After these transactions his reported direct beneficial ownership in common stock reached 827,344 shares, and he also reports additional indirect holdings
Insider purchases by Cryo-Cell International director and 10% owner David Portnoy are reported across September 8-10, 2025. The Form 4 shows multiple open-market purchases of Common Stock at prices between $4.30 and $4.49, including a 5,271-share purchase at a weighted average $4.31 on 09/08/2025 and a series of purchases on 09/09-09/10/2025. The listed transactions total 42,900 shares acquired during the reported dates, and the filing details existing indirect holdings and option positions, including several outstanding stock options covering 529,879 shares in the aggregate. The report is signed by David Portnoy.
Cryo-Cell International, Inc. has scheduled its 2025 Annual Meeting of Stockholders for October 21, 2025. The company set September 15, 2025 as the record date, which means only stockholders of record on that date will be entitled to receive notice of and vote at the meeting.
Stockholders who want to present business or nominate directors at the Annual Meeting must deliver the required notice under the Company’s Bylaws no later than the 10th calendar day after public disclosure of the meeting date, which occurred on September 10, 2025.